Literature DB >> 6141902

Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites.

G Maurer, H R Loosli, E Schreier, B Keller.   

Abstract

Nine ether-extractable metabolites of cyclosporine were isolated from urine of dog and man and from rat bile and feces and purified by preparative HPLC and TLC. Structural assignments were mainly based on spectroscopic data (1H NMR, 13C NMR, MS) and the results of the amino acid analysis after hydrolysis with hydrochloric acid. All the identified metabolites retained the intact cyclic oligopeptide structure of the parent drug. Structural modifications originated from enzymatic oxidation at specific sites of the peptide subunits. Transformation processes principally involved hydroxylation at the terminal carbon atom (eta-position) of the C9-amino acid 1 and the gamma-position of the N-methylleucines 4, 6, and 9, as well as N-demethylation of the N-methylleucine 4. Regioisomeric monohydroxylated cyclosporines (metabolites 1, and 17) and N-demethylcyclosporine (metabolite 21) were the primary metabolites resulting from hydroxylation of the C9-amino-acid 1 and the N-methylleucine 9, and from N-demethylation of the N-methylleucine 4. Dihydroxylated derivatives of cyclosporine (metabolites 8, 10, and 16) were generated by further oxidation of metabolite 1 on one of the other N-methylleucines (4 or 6) or on the C9-amino acid 1, or of metabolite 17 on the N-methylleucine 9. More extensive modifications were observed for metabolite 9, a dihydroxy-N-demethylcyclosporine, which could have been formed from the dihydroxy derivative 16 by N-demethylation or from the N-demethylcyclosporine 21 by dihydroxylation. Metabolite 18 differed from 17 (monohydroxycyclosporine) by the presence of a cyclic ether moiety, formally derived by intramolecular addition of the beta-hydroxyl group to the double bond of the C9-amino acid 1.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6141902

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  35 in total

1.  Mechanism of the ketoconazole-cyclosporin interaction.

Authors:  E Ah-Sing; T W Poole; C Ioannides; L J King
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

2.  Identification of the Aldehydic Metabolites.

Authors:  H Hashem; R Venkataramanan; G J Burckart; L Makowka; T E Starzl; E Fu; L K Wong
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

3.  Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.

Authors:  R Venkataramanan; A Jain; V W Warty; K Abu-Elmagd; H Furakawa; O Imventarza; J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

4.  An unusual side chain C-C cleavage at the MeBmt amino acid in cyclosporin A.

Authors:  A Jegorov; V Havlíček; P Sedmera
Journal:  Amino Acids       Date:  1996-06       Impact factor: 3.520

Review 5.  The cyclosporins.

Authors:  Z Rehácek
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

Review 6.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

7.  Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment.

Authors:  B Legg; M Rowland
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

8.  Excretion of cyclosporine and its metabolites in human bile.

Authors:  G J Burckart; T E Starzl; R Venkataramanan; H Hashim; L Wong; P Wang; L Makowka; A Zeevi; R J Ptachcinski; J E Knapp
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

9.  In vitro model for ciclosporin intestinal absorption in lipid vehicles.

Authors:  J P Reymond; H Sucker
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

Review 10.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.